CN111925360B - 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 - Google Patents

用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Download PDF

Info

Publication number
CN111925360B
CN111925360B CN202010607608.6A CN202010607608A CN111925360B CN 111925360 B CN111925360 B CN 111925360B CN 202010607608 A CN202010607608 A CN 202010607608A CN 111925360 B CN111925360 B CN 111925360B
Authority
CN
China
Prior art keywords
compound
pyrrolidine
tert
mmol
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202010607608.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111925360A (zh
Inventor
谢玲红
菲利普·格林·琼斯
凯瑞·L·斯皮尔
诺尔·阿伦·鲍威尔
泰琳·G·阿纳尼亚
瓦迪姆·亚历山德罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pgi Drug Development Corp
Sumitomo Pharma America Inc
Original Assignee
Pgi Drug Development Corp
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pgi Drug Development Corp, Sunovion Pharmaceuticals Inc filed Critical Pgi Drug Development Corp
Priority to CN202010607608.6A priority Critical patent/CN111925360B/zh
Publication of CN111925360A publication Critical patent/CN111925360A/zh
Application granted granted Critical
Publication of CN111925360B publication Critical patent/CN111925360B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202010607608.6A 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Expired - Fee Related CN111925360B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010607608.6A CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
US62/115,064 2015-02-11
CN202010607608.6A CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
CN201680018639.XA CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680018639.XA Division CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Publications (2)

Publication Number Publication Date
CN111925360A CN111925360A (zh) 2020-11-13
CN111925360B true CN111925360B (zh) 2024-03-22

Family

ID=55456908

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010607608.6A Expired - Fee Related CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
CN201680018639.XA Expired - Fee Related CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680018639.XA Expired - Fee Related CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Country Status (22)

Country Link
US (4) US9856238B2 (enExample)
EP (2) EP4046995B1 (enExample)
JP (3) JP6657241B2 (enExample)
KR (1) KR102601972B1 (enExample)
CN (2) CN111925360B (enExample)
AU (1) AU2016219253C1 (enExample)
CA (1) CA2976095C (enExample)
CY (1) CY1125198T1 (enExample)
DK (1) DK3256466T3 (enExample)
EA (1) EA201791804A1 (enExample)
ES (2) ES2967643T3 (enExample)
HU (1) HUE058698T2 (enExample)
IL (1) IL253914B (enExample)
MX (2) MX371404B (enExample)
MY (1) MY188160A (enExample)
NZ (1) NZ735011A (enExample)
PH (1) PH12017501422A1 (enExample)
PL (1) PL3256466T3 (enExample)
PT (1) PT3256466T (enExample)
SG (2) SG10201806809QA (enExample)
UA (1) UA122222C2 (enExample)
WO (1) WO2016130796A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016219253C1 (en) * 2015-02-11 2022-12-08 Pgi Drug Discovery Llc 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
CA2976092A1 (en) * 2015-02-11 2016-08-18 Sunovion Pharmaceuticals Inc. Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
IL271464B2 (en) 2017-06-30 2024-08-01 Chase Therapeutics Corp NK-1 antagonist compositions and methods for use in the treatment of depression
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
DE69912279T2 (de) 1998-06-30 2004-07-29 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
SE9902267D0 (sv) 1999-06-16 1999-06-16 Astra Ab New compounds
EP1446396A1 (en) * 2001-11-08 2004-08-18 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
JP4738418B2 (ja) * 2004-12-21 2011-08-03 エフ.ホフマン−ラ ロシュ アーゲー クロマン誘導体及びcns障害の処置におけるその使用
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
JP2009524618A (ja) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置における2−イミダゾールの使用
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AU2016219253C1 (en) * 2015-02-11 2022-12-08 Pgi Drug Discovery Llc 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Martial Toffano,et al..Asymmetric routes towards polyfunctionalized pyrrolidines: application to the synthesis of alkaloid analogues.《Tetrahedron: Asymmetry》.2003,第14卷3365-3370. *

Also Published As

Publication number Publication date
EA201791804A1 (ru) 2018-02-28
JP2020079282A (ja) 2020-05-28
NZ735011A (en) 2023-07-28
JP6657241B2 (ja) 2020-03-04
US9856238B2 (en) 2018-01-02
EP4046995A1 (en) 2022-08-24
ES2911910T3 (es) 2022-05-23
ES2967643T3 (es) 2024-05-03
US20190389845A1 (en) 2019-12-26
MY188160A (en) 2021-11-24
SG10201806809QA (en) 2018-09-27
MX371404B (es) 2020-01-29
EP4046995B1 (en) 2023-09-13
IL253914A0 (en) 2017-10-31
CN111925360A (zh) 2020-11-13
PT3256466T (pt) 2022-05-10
KR20170129730A (ko) 2017-11-27
JP2018505205A (ja) 2018-02-22
IL253914B (en) 2021-09-30
WO2016130796A1 (en) 2016-08-18
SG11201706515QA (en) 2017-09-28
AU2016219253B2 (en) 2020-10-01
BR112017017354A2 (pt) 2018-04-10
US20180093974A1 (en) 2018-04-05
US20170001987A1 (en) 2017-01-05
CA2976095A1 (en) 2016-08-18
JP7023994B2 (ja) 2022-02-22
PH12017501422A1 (en) 2018-03-19
PL3256466T3 (pl) 2022-05-23
HUE058698T2 (hu) 2022-09-28
AU2016219253A1 (en) 2017-09-21
MX2017010363A (es) 2018-05-04
EP4046995C0 (en) 2023-09-13
EP3256466B1 (en) 2022-04-06
CA2976095C (en) 2023-10-17
JP2022065050A (ja) 2022-04-26
UA122222C2 (uk) 2020-10-12
ES2911910T9 (es) 2022-08-12
US11192885B2 (en) 2021-12-07
US10336732B2 (en) 2019-07-02
CN107531674A (zh) 2018-01-02
CY1125198T1 (el) 2024-12-13
CN107531674B (zh) 2020-07-31
MX2020001157A (es) 2022-05-27
MX392664B (es) 2025-03-24
EP3256466B9 (en) 2022-07-27
DK3256466T3 (da) 2022-05-02
AU2016219253C1 (en) 2022-12-08
KR102601972B1 (ko) 2023-11-13
US20220185799A1 (en) 2022-06-16
EP3256466A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
JP7023994B2 (ja) Cns疾患を治療するための1-複素環イソクロマニル化合物およびアナログ
US11491133B2 (en) Heteroaryl-isochroman compounds and uses thereof
JP2023036611A (ja) Cns疾患を治療するための縮合ジヒドロ-4h-ピラゾロ[5,1-c][1,4]オキサジニル化合物およびアナログ
HK40042391A (en) 1-heterocyclyl isochromanyl compounds and analogus for treating cns disorders
HK40078692B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40078692A (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK1241876A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK1241876B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EA046724B1 (ru) Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс
BR112017017354B1 (pt) Composto e seu uso, composição, processo para preparar um composto
HK40025044B (en) Isochroman compounds and uses thereof
HK40025044A (en) Isochroman compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042391

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240322

CF01 Termination of patent right due to non-payment of annual fee